PL3035936T3 - CERTAIN CHEMICAL UNITS, COMPOSITIONS AND WAYS - Google Patents

CERTAIN CHEMICAL UNITS, COMPOSITIONS AND WAYS

Info

Publication number
PL3035936T3
PL3035936T3 PL14838403T PL14838403T PL3035936T3 PL 3035936 T3 PL3035936 T3 PL 3035936T3 PL 14838403 T PL14838403 T PL 14838403T PL 14838403 T PL14838403 T PL 14838403T PL 3035936 T3 PL3035936 T3 PL 3035936T3
Authority
PL
Poland
Prior art keywords
ways
compositions
certain chemical
chemical units
units
Prior art date
Application number
PL14838403T
Other languages
Polish (pl)
Inventor
Xiangping Qian
Yong-Liang Zhu
Original Assignee
Neupharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neupharma, Inc. filed Critical Neupharma, Inc.
Publication of PL3035936T3 publication Critical patent/PL3035936T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL14838403T 2013-08-23 2014-08-22 CERTAIN CHEMICAL UNITS, COMPOSITIONS AND WAYS PL3035936T3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361869596P 2013-08-23 2013-08-23
US201361900283P 2013-11-05 2013-11-05
US201462000946P 2014-05-20 2014-05-20
EP14838403.5A EP3035936B1 (en) 2013-08-23 2014-08-22 Certain chemical entities, compositions, and methods
PCT/US2014/052409 WO2015027222A2 (en) 2013-08-23 2014-08-22 Certain chemical entities, compositions, and methods

Publications (1)

Publication Number Publication Date
PL3035936T3 true PL3035936T3 (en) 2019-08-30

Family

ID=52484273

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14838403T PL3035936T3 (en) 2013-08-23 2014-08-22 CERTAIN CHEMICAL UNITS, COMPOSITIONS AND WAYS

Country Status (20)

Country Link
US (9) US20170050936A1 (en)
EP (2) EP3035936B1 (en)
JP (1) JP6559132B2 (en)
KR (1) KR102339228B1 (en)
CN (3) CN105682661B (en)
AU (3) AU2014308616B2 (en)
BR (1) BR112016005199B1 (en)
CA (1) CA2921410C (en)
DK (1) DK3035936T3 (en)
ES (1) ES2729381T3 (en)
HU (1) HUE043465T2 (en)
IL (2) IL244189B (en)
MX (1) MX369863B (en)
NZ (1) NZ718190A (en)
PH (2) PH12019500143B1 (en)
PL (1) PL3035936T3 (en)
PT (1) PT3035936T (en)
RU (1) RU2718876C2 (en)
SG (2) SG11201601138PA (en)
WO (1) WO2015027222A2 (en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
BR112016005199B1 (en) 2013-08-23 2022-02-22 Neupharma, Inc CERTAIN CHEMICAL COMPOUNDS, COMPOSITIONS, AND METHODS
JO3805B1 (en) 2013-10-10 2021-01-31 Araxes Pharma Llc Inhibitors of kras g12c
EP3270694A4 (en) 2015-02-17 2018-09-05 Neupharma, Inc. Certain chemical entities, compositions, and methods
AU2016236669B2 (en) 2015-03-24 2018-11-08 Shanghai Yingli Pharmaceutical Co., Ltd Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
US10259816B2 (en) 2015-04-24 2019-04-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
WO2017005137A1 (en) * 2015-07-03 2017-01-12 吉林大学 Quinazoline compound, intermediate, preparation method, pharmaceutical composition and uses thereof
WO2017012559A1 (en) * 2015-07-21 2017-01-26 广州再极医药科技有限公司 Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
PT3889145T (en) 2015-12-17 2024-04-02 Merck Patent Gmbh 8-CYANO-5-PIPERIDINO-QUINOLINES AS TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATMENT OF IMMUNE DISORDERS
CN106243044A (en) * 2016-06-30 2016-12-21 浙江大学 Pyridine derivatives containing halo acrylamide side chain and preparation and application
CN106279027A (en) * 2016-07-26 2017-01-04 沈阳药科大学 (1 aryl 1H pyrazoles 4 base) (3,4,5 trimethoxyphenyl) ketone, ketoxime compounds and application thereof
CN106187923A (en) * 2016-08-01 2016-12-07 沈阳药科大学 2 aryl 4 aroyl triazole compounds and application thereof
EP4198031A1 (en) * 2016-08-08 2023-06-21 Merck Patent GmbH Tlr7/8 antagonists and uses thereof
WO2018035061A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
HUE053220T2 (en) 2016-11-28 2021-06-28 Teijin Pharma Ltd ((Pyridin-2-yl) amino) pyrido [3,4-d] pyrimidine and ((pyridazin-3-yl) amino) pyrido [3,4-d] pyrimidine derivatives as CDK4 / 6 inhibitors e.g. for the treatment of rheumatoid arthritis, atherosclerosis, pulmonary fibrosis, cerebral infarction or cancer
PE20191133A1 (en) * 2016-11-28 2019-09-02 Teijin Pharma Ltd CRYSTAL DERIVATIVE OF PYRID [3,4-D] PYRIMIDINE OR ITS SOLVATE
EP3573966A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC Fused n-heterocyclic compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
FR3066761B1 (en) * 2017-05-23 2020-10-30 Centre Nat Rech Scient NEW IONIC CHANNEL INHIBITORS
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
CN111032655B (en) * 2017-08-31 2022-09-02 达纳-法伯癌症研究所股份有限公司 EGFR and/or HER2 inhibitors and methods of use
KR102613433B1 (en) 2017-10-11 2023-12-13 주식회사 대웅제약 Novel phenyl pyridine derivatives and pharmaceutical composition comprising the same
AU2019218893B2 (en) * 2018-02-08 2024-12-05 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN108690389A (en) * 2018-04-23 2018-10-23 河北晨阳工贸集团有限公司 A kind of LED light curable water-borne wood coating and preparation method thereof
MX2021000887A (en) 2018-08-01 2021-03-31 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer.
US12351571B2 (en) 2018-12-19 2025-07-08 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
EP3898626A1 (en) * 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
WO2021148396A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US12473300B2 (en) 2020-03-06 2025-11-18 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Thienopyrimidine derivative and preparation method therefor
CN113384582A (en) * 2020-03-13 2021-09-14 广州再极医药科技有限公司 Use of fused ring pyrimidine compounds for the treatment of cancer
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
CN115942937B (en) * 2020-08-17 2025-07-25 浙江扬厉医药技术有限公司 Pyrimido cyclic compounds
JP2023542921A (en) 2020-09-21 2023-10-12 ランドス バイオファーマ インコーポレイテッド NLRX1 ligand
CN117858872A (en) * 2021-06-22 2024-04-09 缆图药品公司 Heterocyclic EGFR inhibitors for the treatment of cancer
WO2022271613A1 (en) * 2021-06-22 2022-12-29 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
CN117940424A (en) * 2021-06-22 2024-04-26 缆图药品公司 EGFR inhibitors
US20240299387A1 (en) * 2021-06-22 2024-09-12 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
CN115583946B (en) * 2021-07-06 2026-01-16 赛诺哈勃药业（成都）有限公司 Heterocyclic compounds and their use as CDK inhibitors
WO2023010354A1 (en) * 2021-08-04 2023-02-09 四川大学华西医院 Small molecule compound having egfr inhibitory activity, and preparation method therefor and use thereof
WO2023071998A1 (en) * 2021-10-26 2023-05-04 杭州德睿智药科技有限公司 Novel pyrido or triazine-substituted pyrido heterocyclic compound
JP2025510910A (en) 2022-03-31 2025-04-15 アストラゼネカ・アクチエボラーグ EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AKT INHIBITORS FOR THE TREATMENT OF CANCER - Patent application
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209084A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
CA3259492A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
KR20250044679A (en) 2022-07-08 2025-04-01 아스트라제네카 아베 Epidermal growth factor receptor tyrosine kinase inhibitors in combination with HGF-receptor inhibitors for cancer treatment
AU2024290917A1 (en) * 2023-07-03 2026-01-22 Cervero Therapeutics, LLC Polo-like kinase 1 inhibitors
WO2025235874A1 (en) * 2024-05-10 2025-11-13 Schrödinger, Inc. Heterocyclics as egfr inhibitors

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB587936A (en) 1944-09-05 1947-05-09 Francis Henry Swinden Curd New quinazoline derivatives
GB8515934D0 (en) 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (en) 1994-03-25 2008-03-16 Isotechnika, Inc. IMPROVEMENT OF THE EFFECTIVENESS OF PHARMACOS BY DEUTERATION.
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2241551A1 (en) 1996-02-12 1997-08-14 Rutgers, The State University Of New Jersey Coralyne analogs as topoisomerase inhibitors
DE69720965T2 (en) 1996-02-13 2004-02-05 Astrazeneca Ab CHINAZOLE DERIVATIVES AND THEIR USE AS VEGF INHIBITORS
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JP3990061B2 (en) 1998-01-05 2007-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 Purine derivatives and adenosine A2 receptor antagonists as preventive and therapeutic agents for diabetes
AU1688599A (en) 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PT1154774E (en) 1999-02-10 2005-10-31 Astrazeneca Ab QUINAZOLINE DERIVATIVES AS ANGIOGENESE INHIBITORS
US6841549B1 (en) 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
AU7031500A (en) * 1999-09-23 2001-04-24 Astrazeneca Ab Therapeutic quinazoline compounds
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (en) 2000-06-06 2005-10-17 Астразенека Аб Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
MXPA02012903A (en) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors.
MXPA02012905A (en) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents.
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
WO2004082606A2 (en) 2003-03-13 2004-09-30 Synta Pharmaceuticals Corp. Fused pyrrole compounds
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
JP5118972B2 (en) 2004-10-29 2013-01-16 テイボテク・フアーマシユーチカルズ HIV inhibitory bicyclic pyrimidine derivatives
CR9465A (en) 2005-03-25 2008-06-19 Surface Logix Inc PHARMACOCINETICALLY IMPROVED COMPOUNDS
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
AR060358A1 (en) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic QUINAZOLINS FOR THE INHIBITION OF PDK 1
TWI389893B (en) 2007-07-06 2013-03-21 Astellas Pharma Inc Di (arylamino) ary1 compound
EP2215094B1 (en) 2007-11-15 2016-01-27 YM BioSciences Australia Pty Ltd N-containing heterocyclic compounds
CN102015660A (en) * 2008-04-23 2011-04-13 协和发酵麒麟株式会社 2-aminoquinazoline derivatives
US8252791B2 (en) 2008-08-13 2012-08-28 Jenrin Discovery, Inc. Purine compounds as cannabinoid receptor blockers
WO2010056758A1 (en) 2008-11-12 2010-05-20 Yangbo Feng Quinazoline derivatives as kinase inhibitors
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
JP5941407B2 (en) 2009-10-07 2016-06-29 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ HSP90 inhibitor
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
WO2011079231A1 (en) * 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
FR2959510B1 (en) * 2010-04-28 2013-04-26 Centre Nat Rech Scient PYRIDO [3,2-D] PYRIMIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC USES
CN102260263A (en) 2010-05-26 2011-11-30 四川大学 Diphenylamine purine derivatives, and preparation method and medicinal application thereof
JP6147727B2 (en) 2011-04-01 2017-06-14 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション Substituted N- (3- (pyrimidin-4-yl) phenyl) acrylamide analogs as tyrosine receptor kinase BTK inhibitors
WO2013005157A1 (en) 2011-07-05 2013-01-10 Lupin Limited Sulfone derivatives and their use as pkm2 modulators for the treatment of cancer
US8796289B2 (en) * 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
EP4119551A1 (en) 2011-07-27 2023-01-18 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine compounds
ES2725790T3 (en) 2011-08-26 2019-09-27 Neupharma Inc Some chemical entities, compositions, and methods
CN115403531A (en) 2011-09-14 2022-11-29 润新生物公司 Chemical entities, compositions, and methods as kinase inhibitors
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
WO2013106792A1 (en) 2012-01-13 2013-07-18 Acea Biosciences Inc. Heterocyclic compounds and uses as anticancer agents.
TW201336847A (en) 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd Quinolyl pyrrolopyrimidine compound or salt thereof
TW201348226A (en) * 2012-02-28 2013-12-01 Amgen Inc Amides as Pim inhibitors
SG11201500125QA (en) 2012-07-11 2015-02-27 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
TW201427958A (en) 2012-09-14 2014-07-16 Univ Nat Yang Ming Aryl amine substituted pyrimidine and quinazoline and their use as anticancer drugs
KR102215272B1 (en) 2012-09-28 2021-02-15 이그니타, 인코포레이티드 Azaquinazoline inhibitors of atypical protein kinase c
CN103864792B (en) 2012-12-12 2017-01-18 山东亨利医药科技有限责任公司 Heterocyclic nitrogen compound acting as tyrosine kinase inhibitor
CN103936742B (en) 2013-01-17 2017-05-03 程鹏 Novel PI3K inhibitor containing purine radicals, preparation method and applications thereof
US9708326B2 (en) 2013-02-25 2017-07-18 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
EP2964648B1 (en) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
EP2964638B1 (en) 2013-03-06 2017-08-09 Astrazeneca AB Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
WO2014180524A1 (en) 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
CN103554038B (en) 2013-06-19 2015-10-14 云南大学 Phenyl polyhalide nitrile quinazolinones and its production and use
KR102173433B1 (en) 2013-07-11 2020-11-04 에이시아 바이오사이언시스 인코포레이티드. Pyrimidine derivatives as kinase inhibitors
MX360498B (en) 2013-08-12 2018-11-05 Taiho Pharmaceutical Co Ltd Novel fused pyrimidine compound or salt thereof.
BR112016005199B1 (en) 2013-08-23 2022-02-22 Neupharma, Inc CERTAIN CHEMICAL COMPOUNDS, COMPOSITIONS, AND METHODS
CA2922044A1 (en) 2013-10-18 2015-05-14 Medivation Technologies, Inc. Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
GB201404987D0 (en) 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
WO2015151006A1 (en) 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
US9840520B2 (en) 2014-05-14 2017-12-12 The Regents Of The University Of Colorado, A Body Corporate Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
CN104086551B (en) 2014-06-06 2016-09-21 人福医药集团股份公司 Compound and its production and use
US9949971B2 (en) 2014-06-17 2018-04-24 Acerta Pharma B.V. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
CN105315283A (en) 2014-07-22 2016-02-10 成都贝斯凯瑞生物科技有限公司 Bruton tyrosine kinases inhibitor
AU2015296215A1 (en) 2014-08-01 2017-03-23 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016110821A1 (en) 2015-01-08 2016-07-14 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
CN105837576B (en) 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 BTK inhibitors
EP3270694A4 (en) 2015-02-17 2018-09-05 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN105777759B (en) 2016-04-29 2018-01-26 杭州和正医药有限公司 A kind of bruton's tyrosine kinase inhibitor
WO2018035061A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods

Also Published As

Publication number Publication date
US10653701B2 (en) 2020-05-19
CN111285813A (en) 2020-06-16
US12403145B2 (en) 2025-09-02
AU2019201461A1 (en) 2019-03-28
US20180125855A1 (en) 2018-05-10
CN105682661B (en) 2020-03-27
MX369863B (en) 2019-11-25
US11304957B2 (en) 2022-04-19
AU2014308616A1 (en) 2016-03-10
RU2016110412A3 (en) 2018-06-22
US20150175601A1 (en) 2015-06-25
US20190307767A1 (en) 2019-10-10
US20240197752A1 (en) 2024-06-20
EP3508204A1 (en) 2019-07-10
SG10201908045VA (en) 2019-10-30
MX2016002137A (en) 2017-02-15
CA2921410A1 (en) 2015-02-26
EP3035936B1 (en) 2019-03-13
US20170196881A1 (en) 2017-07-13
CA2921410C (en) 2023-03-28
DK3035936T3 (en) 2019-06-11
EP3508204B1 (en) 2026-02-11
KR102339228B1 (en) 2021-12-13
RU2016110412A (en) 2017-09-26
US20260102406A1 (en) 2026-04-16
IL268094B (en) 2020-07-30
AU2019201461B2 (en) 2020-11-12
RU2718876C2 (en) 2020-04-15
CN105682661A (en) 2016-06-15
KR20160090786A (en) 2016-08-01
CN109851617B (en) 2022-08-16
WO2015027222A3 (en) 2015-04-16
PH12019500143A1 (en) 2020-03-02
HK1226939A1 (en) 2017-10-13
EP3035936A4 (en) 2017-03-08
JP6559132B2 (en) 2019-08-14
ES2729381T3 (en) 2019-11-04
WO2015027222A2 (en) 2015-02-26
US9550770B2 (en) 2017-01-24
US20200306259A1 (en) 2020-10-01
PH12019500143B1 (en) 2023-03-24
AU2021200372B2 (en) 2023-09-21
US20170050936A1 (en) 2017-02-23
NZ718190A (en) 2017-10-27
US9849139B2 (en) 2017-12-26
PT3035936T (en) 2019-06-18
HUE043465T2 (en) 2019-08-28
EP3035936A2 (en) 2016-06-29
AU2021200372A1 (en) 2021-03-18
IL268094A (en) 2019-09-26
US11865120B2 (en) 2024-01-09
PH12016500330B1 (en) 2016-05-02
US20220354864A1 (en) 2022-11-10
US10172868B2 (en) 2019-01-08
AU2014308616B2 (en) 2018-12-06
IL244189B (en) 2019-08-29
SG11201601138PA (en) 2016-03-30
IL244189A0 (en) 2016-04-21
JP2016530274A (en) 2016-09-29
BR112016005199A2 (en) 2017-08-01
PH12016500330A1 (en) 2016-05-02
CN109851617A (en) 2019-06-07
BR112016005199B1 (en) 2022-02-22

Similar Documents

Publication Publication Date Title
PL3035936T3 (en) CERTAIN CHEMICAL UNITS, COMPOSITIONS AND WAYS
FR3006466B3 (en) .
DK2984138T3 (en) polymer Composition
DK2986726T3 (en) HOWEVER, UNKNOWN BACILLUS STUDY COMPOSITIONS
CL2016000258A1 (en) Sweetening compositions
CL2016000257A1 (en) Sweetening compositions
EP2889350A4 (en) TOUCH-ADHESIVE COMPOSITION
BR302014001381S1 (en) Bag-applied configuration.
EP2989885A4 (en) COMBINE
BR112016010669A2 (en) disinfectant composition
EP2968338A4 (en) NEW USES
DK3027750T3 (en) BIOKATALYTICAL COMPOSITION
SI2976084T1 (en) Combination containing zidovudine and prolimyxin
IL240626A0 (en) Social context for applications
DK2975030T3 (en) DIHYDROPYRIDAZINE-3,5-DION-DERIVATIVE
EP2956141A4 (en) NEW USES
DK3071053T3 (en) PREBIOTIC COMPOSITION
EP3012307A4 (en) MIXED REFRIGERIGENE
FR3001302B1 (en) .
DK3003298T3 (en) ANTIFIBROGEN COMPOUNDS, PROCESSES AND USES THEREOF
EP2977504A4 (en) DEHUMIDIFIER
EP3004139A4 (en) SELECTIN INHIBITORS, COMPOSITION, AND USES THEREOF
EP2966216A4 (en) DEHUMIDIFIER
FR3001303B1 (en) .
FI10329U1 (en) gas treatment